Next-Gen Drug Discovery.
The premier conference series for life-science leaders, R&D directors, and AI scientists examining how machine intelligence is compressing discovery timelines, reshaping clinical trials, and unlocking precision medicine at population scale.
Date
22 September 2027
Venue
Central London
Format
In-person Panel Based Discussions
Series
World Pharma AI
The London Edition
Six focus areas, mapped to the decisions clinical and health-system leaders face right now.
Foundation models, generative chemistry, and ML-driven target identification compressing the path from hypothesis to candidate molecule.
Adaptive trial design, synthetic control arms, recruitment, and the operational AI reshaping how trials are run.
Multi-omics, biomarker discovery, and the AI translating genomic signal into targeted, individualised therapy.
Navigating FDA, EMA, and global frameworks for AI-enabled drug development, validation, and submission.
Harnessing real-world data, EHRs, and registries to generate evidence across the product lifecycle.
Predictive quality, process optimisation, and resilient pharmaceutical supply chains powered by machine learning.
Signal detection, adverse-event monitoring, and AI-augmented drug safety at scale.
Where capital, platforms, and AI-native biotech meet — the business of intelligent drug development.
Passes
Complimentary pass for C-Suite Executives & Directors. Subject to confirmation.
Who qualifies
Vendors (Service Providers)
Includes
Partnership & exhibition packages for solution providers.
Opportunities include